Hi Tom, is there any news from the korean lab members taking ß-L? Do they still take it? Any experienced Side-Effects?
Hi Ethic,
unfortunately I dont speak to him anymore since a few time now and do not feel confortable to disturb him again as he does not work on beta-lapachone again. Some others of his team does.
from what he told me he was willing to use beta lapachone for its long lasting property on a transient and frequent use. But actually to answer your question I prefer to directly quote him here because I dont have more than that answer regarding your concern:
"I don't have human data for the synthetic beta laphachone. Some people including me have taken the bL extract, 3 tablets per day, but lead to no side effects as bodily symptoms and normal blood measures. In my case, there is no beneficial effects because I have no health problem. My father in law suffered from cancer in the urinary bladder took it and fully recovered but he also received surgery without anti-cancer therapy in hospital. You know there is no drug for uridary bladder cancer and surgical removal is the only way. In addition, I heard that many people reported dramaticd effects but these results could not be scientifically proved.I don't study the bL anymore but sometime I will take it if sometime I need it."
Here they found out that NADH increased following cisplatin damage induced on hearing and that NAD+ level was well increased by beta lapachone treatment: http://www.ncbi.nlm....pubmed/24922076
Cisplatin (cis-diaminedichloroplatinum-II) is an extensively used chemotherapeutic agent, and one of its most adverse effects is ototoxicity. A number of studies have demonstrated that these effects are related to oxidative stress and DNA damage. However, the precise mechanism underlying cisplatin-associated ototoxicity is still unclear. The cofactor nicotinamide adenine dinucleotide (NAD+) has emerged as a key regulator of cellular energy metabolism and homeostasis. Here, we demonstrate for the first time that, in cisplatin-mediated ototoxicity, the levels and activities of SIRT1 are suppressed by the reduction of intracellular NAD+ levels. We provide evidence that the decrease in SIRT1 activity and expression facilitated by increasing poly(ADP-ribose) transferase (PARP)-1 activation and microRNA-34a through p53 activation aggravates cisplatin-mediated ototoxicity. Moreover, we show that the induction of cellular NAD+ levels using β-lapachone (β-Lap), whose intracellular target is NQO1, prevents the toxic effects of cisplatin through the regulation of PARP-1 and SIRT1 activity. These results suggest that direct modulation of cellular NAD+ levels by pharmacological agents could be a promising therapeutic approach for protection from cisplatin-induced ototoxicity.
This full study confirm the fact that the ratio is what is important once again. You can check their graph at the end of the study (external link picture)
I believe beta-lapachone is much more potent to control the NAD+ metabolism than NR because NR will remain only for short term.. and this seems to be validated by the chromadex studies that advice a continual use of NR to feed a pool perforated
Hi Tom, I dont understand the ratio discussion. The only thing it tells you is that something has changed in the metabolism compared to an earlier situation. For humans it is known this ratio shifts as we age and that NAD+ declines a lot. But ones you start to thinker with the cell metabolism the ratio doesn't tell too much in my opinion. For example if the thinkering leads to doubling of both NAD+ and NADH I think we would be better off bit and the ratio is unchanged.
The big difference with NR is that NR is a path that injects NAD+ from external. Here we are talking about salvage path and possible redistribution. LIke I said earlier I find it interesting and lets see what more study reveals so I will stay in this discussion. Personally however it will not change my view on NR and its usefulness. NR has good track record so far and clear mechanism.
Hi Stefan, I think I already gave enough paper reference here about that, it seems clear that the ratio play a huge role on the health and it is actually also proven in vivo in numerous studies as you seen. And as you admited: aging shift this ratio.
I dont think NR should be seen as an ennemy for beta-lapachone (or the opposite). The only thing is that the NAD+ pool is perforated and you have to use both. As you know aging is a multi factor disease you we need to think in an holistic approach:
Personally my top 3 would be:
beta-lapachone (its long-lasting property is critical for the transitent and frequent increase of NAD+/NADH ratio.)
NR ( as a precursor for the NAD+ pool) but this time as low dose since no need for high dose (wich is actually a bad thing on the long run), small dose will be enough if beta-lapachone is used in a transitent way
Pterostilbene (the best SIRT1 activator so far)
here you almost control the full aging metabolism. The scientist was also interested by this combination. I would love to see someone able to test that on mice
Hi Tom, well if you think that's enough papers and proof then I stop the discussion. I think there are a lot of holes that may or may not be filled by future research. Also you continue to make statements which I find wrong. You state very easily that NR is "bad in the long term" but you have no such concerns on this product which frankly has never been tested in humans. Sounds like double standards to me.
Edited by stefan_001, 30 May 2016 - 02:01 PM.